Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease.
about
Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disordersNeuroimaging of Parkinson's disease: Expanding views.The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.Investigation of Apparent Diffusion Coefficient from Ultra-high b-Values in Parkinson's Disease.Usefulness of R2* maps generated by iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantitation sequence for cerebral artery dissection.R2* Map by IDEAL IQ for Acute Cerebral Infarction: Compared with Susceptibility Vessel Sign on T2*-Weighted Imaging.Multi-View Ensemble Classification of Brain Connectivity Images for Neurodegeneration Type DiscriminationA multicontrast approach for comprehensive imaging of substantia nigra.Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson's Disease: A Study on Substantia Nigra and Striatum.The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.Diffusion Kurtosis Imaging of Substantia Nigra Is a Sensitive Method for Early Diagnosis and Disease Evaluation in Parkinson's Disease.T2-relaxometry predicts outcome of DBS in idiopathic Parkinson's disease.Imaging synucleinopathies.Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinson's Disease: Challenging Results.Magnetic resonance imaging for the diagnosis of Parkinson's disease.Frontal white matter injuries predestine gait difficulties in Parkinson's disease.Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.Chemical Exchange Saturation Transfer MRI Signal Loss of the Substantia Nigra as an Imaging Biomarker to Evaluate the Diagnosis and Severity of Parkinson's Disease.Application of high-field magnetic resonance imaging in Parkinson's disease.Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.The Aging of Iron Man.
P2860
Q26766362-A5EA4711-0E99-4C14-84FE-A7E32FF41D19Q28387732-D5EF54DE-3E1A-46A9-B1B7-5170C028B735Q30829363-7F47FDD6-1F6D-449D-A0CA-355023B7D559Q30906473-0115513F-FB84-4191-A1D9-7179C01CFB61Q30970801-4B7FCB8E-61D5-47CC-A098-B299A340912BQ31135111-D31C8F3C-58A9-451D-AD6E-2085B89CF150Q33726005-0E924F5B-A8DB-425F-8F50-6AE8E09BF514Q35555926-BA109978-77C0-4F24-9057-CD57257CC9A2Q35976522-7E66AEAA-EC07-4F67-A3BA-303483F78FA3Q36174326-40BAEFA6-576B-4E75-8791-E4C72F5DD628Q36332532-82125726-B3B9-4DC6-8A46-897E723F86B3Q36378779-1FCD18CD-F0F5-4B70-A81E-9617FCD852F5Q37396921-B4394A4A-2D29-4B32-A706-EC10CC565A2CQ38734660-C5B3805B-D57D-4060-821F-29AABC88F60EQ39010365-8ABC6630-B59A-49A0-8A1E-C6C3BECAEE96Q39220904-163CA672-70AC-4C84-BE99-F88658AECAB4Q39552785-587757D1-65EB-4052-854D-56E13B5F3284Q39877122-8BEEB4E7-5F10-48C6-B19B-1B01CB82AEBAQ40202363-E25707B6-DD9A-4907-A401-F68554276297Q41608046-CF79D08E-6182-4B48-BFD9-CBCA9271D91CQ42247149-CEF79095-64DF-4E99-81CC-1A73D7AC38BEQ47183452-4FD26D12-212D-4B60-B1C2-B31808375871Q51758684-EF643D1D-035A-4AE6-9F8C-0AABBE6DF43A
P2860
Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@en
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@nl
type
label
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@en
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@nl
prefLabel
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@en
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@nl
P2093
P2860
P50
P1476
Substantia nigra in Parkinson' ...... dvanced stages of the disease.
@en
P2093
Antonio Emanuele Elia
Laura Farina
Luigi Romita
Marina Grisoli
P2860
P2888
P304
P356
10.1007/S10072-013-1595-2
P50
P577
2013-12-11T00:00:00Z